Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients


Arslan U. Y. , Turker I., Aksoy S., Oksuzoglu B., Helvaci K., Ozdemir N. Y. , ...Daha Fazla

JOURNAL OF BUON, cilt.18, ss.585-593, 2013 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 18 Konu: 3
  • Basım Tarihi: 2013
  • Dergi Adı: JOURNAL OF BUON
  • Sayfa Sayıları: ss.585-593

Özet

Purpose: The duration of anti-HER2 blockage therapy in metastatic breast cancer patients is still unclear. We aimed to evaluate the effect of the anti-HER2 blockage therapy duration and other factors on survival in HER2 positive metastatic breast carcinoma (MBC) patients.